Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ATLCAR.CD30 cells||CAR.CD30-expressing Autologous T Lymphocytes||ATLCAR.CD30 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor that targets CD30, potentially leading to immune response against CD30-positive tumor cells (PMID: 30841880).|
|ATLCAR.CD30.CCR4 cells||ATLCAR.CD30-CD28zeta-CCR4 cells||ATLCAR.CD30.CCR4 cells are autologous T-lymphocytes that are engineered to express CCR4 linked to a chimeric antigen receptor that recognizes CD30 and the co-stimulatory domains of CD28 and CD3zeta, which potentially results in increased immune response against CD30-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03602157||Phase I||ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells||Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL||Recruiting||USA||0|